Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Next Previous
X
Search
Trial Profile

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REMIT-iGL

    • Most Recent Events

    • 20 Oct 2023 Results examining whether remission can be achieved by combining lifestyle approaches and short-term intensive glucose-lowering therapy, published in the Diabetes, Obesity and Metabolism
    • 29 Jun 2021 Primary endpoint (The first occurrence of diabetes relapse) has been met, as per results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 29 Jun 2021 Results (n=160) assessing induction of diabetes remission following a short-term treatment with insulin glargine, lixisenatide and metformin and changes in exercise and dietary behaviours, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top